Skip to main content
PMC home page
Gut logoLink to Gut
. 1996 Jan;38(1):125–128. doi: 10.1136/gut.38.1.125

Chemoembolisation with lipiodol and doxorubicin: applicability in British patients with hepatocellular carcinoma.

S D Ryder 1, P M Rizzi 1, E Metivier 1, J Karani 1, R Williams 1
PMCID: PMC1382990  PMID: 8566839

Abstract

Chemoembolisation has been extensively used as primary treatment for unresectable hepatocellular carcinoma (HCC). In this unit, 185 patients with a new diagnosis of HCC not amenable to surgery were seen between 1988 and 1991. Intended therapy for these patients was chemoembolisation with doxorubicin (60 mg/m2) and lipiodol, repeated at six week intervals until it was technically no longer possible or until complete tumour response had been obtained. Chemoembolisation was possible in 67 of the 185 (37%). Reasons for exclusion were portal vein occlusion (n = 36), decompensated cirrhosis (n = 44), distant metastases (n = 5), diffuse tumour or unsuitable anatomy (tumour or vasculature) (n = 11), patient refusal (n = 11), and other (n = 11). Patients excluded from treatment survived for a median of 10 weeks (range 3 days-19 months). In patients treated, 18 had small HCC (< 4 cm) and 49 had large or multifocal HCC. Chemoembolisation was carried out a median of two sessions for small and three sessions for large tumours. Ten of 18 patients with small HCC showed a 50% or greater reduction in tumour size. Five of 49 patients with large or multifocal tumours showed a response to treatment. Median overall survival for treated patients was 36 weeks (range 3 days-4 years). One patient has subsequently undergone liver transplantation with no recurrence and minimal residual disease at transplantation. Two other patients are alive three years after chemoembolisation, one with no evidence of recurrent disease. No patient was thought suitable for surgery after their response to chemoembolisation. Chemotherapy related complications were seen in 22%. Complications were significantly more common in patients with larger tumours and poor liver reserve. Five patients died as a result of chemotherapy related complications. In conclusion, only one third of UK patients with unresectable HCC are treatable by chemoembolisation. Results with small tumours are encouraging, with a high response rate and the possibility of surgical intervention in previously inoperable disease. Large tumours, however, show a poor response and a significant incidence of side effects, suggesting that this treatment offers little benefit in advanced disease.

Full text

PDF
128

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allison D. J., Jordan H., Hennessy O. Therapeutic embolisation of the hepatic artery: a review of 75 procedures. Lancet. 1985 Mar 16;1(8429):595–599. doi: 10.1016/s0140-6736(85)92142-7. [DOI] [PubMed] [Google Scholar]
  2. Bismuth H., Morino M., Sherlock D., Castaing D., Miglietta C., Cauquil P., Roche A. Primary treatment of hepatocellular carcinoma by arterial chemoembolization. Am J Surg. 1992 Apr;163(4):387–394. doi: 10.1016/0002-9610(92)90039-t. [DOI] [PubMed] [Google Scholar]
  3. Bronowicki J. P., Vetter D., Dumas F., Boudjema K., Bader R., Weiss A. M., Wenger J. J., Boissel P., Bigard M. A., Doffoel M. Transcatheter oily chemoembolization for hepatocellular carcinoma. A 4-year study of 127 French patients. Cancer. 1994 Jul 1;74(1):16–24. doi: 10.1002/1097-0142(19940701)74:1<16::aid-cncr2820740105>3.0.co;2-v. [DOI] [PubMed] [Google Scholar]
  4. Chen S. C., Hsieh M. Y., Chuang W. L., Wang L. Y., Chang W. Y. Development of portal vein invasion and its outcome in hepatocellular carcinoma treated by transcatheter arterial chemo-embolization. J Gastroenterol Hepatol. 1994 Jan-Feb;9(1):1–6. doi: 10.1111/j.1440-1746.1994.tb01207.x. [DOI] [PubMed] [Google Scholar]
  5. Elba S., Giannuzzi V., Misciagna G., Manghisi O. G. Randomized controlled trial of tamoxifen versus placebo in inoperable hepatocellular carcinoma. Ital J Gastroenterol. 1994 Mar;26(2):66–68. [PubMed] [Google Scholar]
  6. Farinati F., De Maria N., Fornasiero A., Salvagnini M., Fagiuoli S., Chiaramonte M., Naccarato R. Prospective controlled trial with antiestrogen drug tamoxifen in patients with unresectable hepatocellular carcinoma. Dig Dis Sci. 1992 May;37(5):659–662. doi: 10.1007/BF01296419. [DOI] [PubMed] [Google Scholar]
  7. Ikeda K., Kumada H., Saitoh S., Arase Y., Chayama K. Effect of repeated transcatheter arterial embolization on the survival time in patients with hepatocellular carcinoma. An analysis by the Cox proportional hazard model. Cancer. 1991 Nov 15;68(10):2150–2154. doi: 10.1002/1097-0142(19911115)68:10<2150::aid-cncr2820681011>3.0.co;2-f. [DOI] [PubMed] [Google Scholar]
  8. Kanematsu T., Furuta T., Takenaka K., Matsumata T., Yoshida Y., Nishizaki T., Hasuo K., Sugimachi K. A 5-year experience of lipiodolization: selective regional chemotherapy for 200 patients with hepatocellular carcinoma. Hepatology. 1989 Jul;10(1):98–102. doi: 10.1002/hep.1840100119. [DOI] [PubMed] [Google Scholar]
  9. Kasugai H., Kojima J., Tatsuta M., Okuda S., Sasaki Y., Imaoka S., Fujita M., Ishiguro S. Treatment of hepatocellular carcinoma by transcatheter arterial embolization combined with intraarterial infusion of a mixture of cisplatin and ethiodized oil. Gastroenterology. 1989 Oct;97(4):965–971. doi: 10.1016/0016-5085(89)91505-9. [DOI] [PubMed] [Google Scholar]
  10. Livraghi T., Bolondi L., Lazzaroni S., Marin G., Morabito A., Rapaccini G. L., Salmi A., Torzilli G. Percutaneous ethanol injection in the treatment of hepatocellular carcinoma in cirrhosis. A study on 207 patients. Cancer. 1992 Feb 15;69(4):925–929. doi: 10.1002/1097-0142(19920215)69:4<925::aid-cncr2820690415>3.0.co;2-g. [DOI] [PubMed] [Google Scholar]
  11. Madden M. V., Krige J. E., Bailey S., Beningfield S. J., Geddes C., Werner I. D., Terblanche J. Randomised trial of targeted chemotherapy with lipiodol and 5-epidoxorubicin compared with symptomatic treatment for hepatoma. Gut. 1993 Nov;34(11):1598–1600. doi: 10.1136/gut.34.11.1598. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Martínez Cerezo F. J., Tomás A., Donoso L., Enríquez J., Guarner C., Balanzó J., Martínez Nogueras A., Vilardell F. Controlled trial of tamoxifen in patients with advanced hepatocellular carcinoma. J Hepatol. 1994 Jun;20(6):702–706. doi: 10.1016/s0168-8278(05)80138-2. [DOI] [PubMed] [Google Scholar]
  13. Mondazzi L., Bottelli R., Brambilla G., Rampoldi A., Rezakovic I., Zavaglia C., Alberti A., Idèo G. Transarterial oily chemoembolization for the treatment of hepatocellular carcinoma: a multivariate analysis of prognostic factors. Hepatology. 1994 May;19(5):1115–1123. [PubMed] [Google Scholar]
  14. Ngan H., Lai C. L., Fan S. T., Lai E. C., Yuen W. K., Tso W. K. Treatment of inoperable hepatocellular carcinoma by transcatheter arterial chemoembolization using an emulsion of cisplatin in iodized oil and gelfoam. Clin Radiol. 1993 May;47(5):315–320. doi: 10.1016/s0009-9260(05)81446-1. [DOI] [PubMed] [Google Scholar]
  15. Pelletier G., Roche A., Ink O., Anciaux M. L., Derhy S., Rougier P., Lenoir C., Attali P., Etienne J. P. A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. J Hepatol. 1990 Sep;11(2):181–184. doi: 10.1016/0168-8278(90)90110-d. [DOI] [PubMed] [Google Scholar]
  16. Takayasu K., Shima Y., Muramatsu Y., Moriyama N., Yamada T., Makuuchi M., Hasegawa H., Hirohashi S. Hepatocellular carcinoma: treatment with intraarterial iodized oil with and without chemotherapeutic agents. Radiology. 1987 May;163(2):345–351. doi: 10.1148/radiology.163.2.3031724. [DOI] [PubMed] [Google Scholar]
  17. Yoshimi F., Nagao T., Inoue S., Kawano N., Muto T., Gunji T., Ohnishi S., Imawari M. Comparison of hepatectomy and transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma: necessity for prospective randomized trial. Hepatology. 1992 Sep;16(3):702–706. doi: 10.1002/hep.1840160314. [DOI] [PubMed] [Google Scholar]
  18. Yu Y. Q., Xu D. B., Zhou X. D., Lu J. Z., Tang Z. Y., Mack P. Experience with liver resection after hepatic arterial chemoembolization for hepatocellular carcinoma. Cancer. 1993 Jan 1;71(1):62–65. doi: 10.1002/1097-0142(19930101)71:1<62::aid-cncr2820710111>3.0.co;2-8. [DOI] [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES